A 90-Minute Bus Ride and Three Missed Appointments: Choosing and Delivering a Long-Acting Injectable

Recommendation: aripiprazole long-acting injectable, using a formulation and interval that minimize visits.

Why this over the alternatives:

Option	Consideration
Aripiprazole monohydrate (monthly, with a 2-month 960 mg option)	Best metabolic profile of the realistic choices - directly addresses his prior 9 kg risperidone-related gain and BMI of 31. He is already tolerating oral aripiprazole, so the required oral tolerability test is satisfied. A 2-month interval halves his travel burden.
Aripiprazole lauroxil	Also reasonable; comes with a no-oral-tolerance-test path and 1-, 2-, and 4-month (Aristada Initio) options - useful if oral adherence is unreliable, though he is currently taking oral medication.
Risperidone LAI	Tolerability is established, and it is cheap, but the prior 9 kg gain and hyperprolactinemia risk make it the weaker choice for a young man with metabolic risk.
Paliperidone palmitate	Convenient intervals (1- and 3-month, 6-month), but weight gain/prolactin risk and no prior exposure.

Transition plan:

• Continue oral aripiprazole 15 mg daily for 14 days after the first injection (overlap is required with aripiprazole monohydrate to maintain levels).
• First injection 400 mg IM deltoid or gluteal; steady state takes ~4 months, so do not drop oral coverage prematurely.
• Once stabilized on monthly 400 mg, move to the 2-month 960 mg regimen per labeling.
• Note his mild akathisia - aripiprazole can worsen it; consider dose, propranolol, or reassessment before injecting and monitor closely in the first weeks.
• Address the stigma comment explicitly: frame the injection as "one visit every two months instead of two pills every day," which fits his self-image better than daily reminders of illness.

A depot does not fix a delivery problem - the barrier here is geography and schedule, not motivation.

Structural fixes:

1. Extend the interval (2-month dosing) to cut round trips from 12 to 6 per year.
2. Bring the injection to him: home/community-based nurse administration, a depot clinic nearer his home, or administration at a site aligned with his shift pattern. Ask the clinic's case manager or home-health liaison.
3. Transport: bus vouchers, mileage/rideshare, or scheduling on days he already has off; align appointments to his posted shift roster.
4. Reminders: text/call reminders 48 hours and 2 hours before; pair the appointment with something he values (a coffee, a preferred clinician).
5. Telehealth for the non-injection visits so clinic trips are reserved for injections.

Behavioral/relational work:

• Use motivational interviewing rather than warnings: elicit his own reasons (job, independence, avoiding hospitalization) and reflect the ambivalence about "feeling like a patient."
• Explicitly name the trade-off he has already discovered: he stopped medication because he felt well and gained weight; the LAI plus a metabolic plan is a direct response to his stated reasons.
• Cannabis: use a harm-reduction stance - ask about function, motivation, and symptom effects; avoid ultimatums that drive disengagement; note that ongoing heavy use predicts relapse and poorer LAI persistence.
• Address negative symptoms with psychosocial rehabilitation (supported employment, social skills) rather than medication escalation.
• Engage a family member or friend (with his consent) as a support and reminder partner.
• Write a relapse action plan with early warning signs and a same-day contact.

Define success up front and measure it.

Process/implementation measures:

• Injections received on time (target: all scheduled injections within the allowed window).
• Appointment attendance rate versus the current 40%.
• Time to relapse, hospitalizations, ED visits, and any gaps in coverage.

Clinical monitoring:

• Akathisia and EPS at each visit (he has baseline akathisia); AIMS at baseline and every 6 months, more often if symptoms emerge.
• Metabolic panel: weight, BMI, waist, blood pressure, fasting glucose/A1c and lipids at baseline, 3 months, then every 6 months - he is already BMI 31 with a prior drug-induced 9 kg gain.
• Prolactin only if symptomatic (gynecomastia, galactorrhea, sexual dysfunction) - low yield with aripiprazole.
• Symptom and function measures: a brief symptom rating, plus a functional target (keeping the warehouse job, return to school).
• Cannabis and substance use at each visit, non-judgmentally.
• Injection-site reactions, and any emergence of impulse-control behaviors (pathologic gambling, hypersexuality) - uncommon but aripiprazole-associated and easy to miss.

Decision rules:

• If akathisia becomes intolerable, reduce dose or add propranolol before abandoning the LAI.
• If he misses an injection window, same-week outreach - do not wait for the next cycle.
• If two consecutive relapses occur despite adherence, rethink the diagnosis and drug choice rather than the delivery format.

Document the shared plan so the next clinician does not restart oral therapy "because he missed appointments."